MEDFORD, Mass., and HEIDELBERG, Germany, April 22 /PRNewswire/ -- febit holding gmbh today announced it will introduce the Geniom RT Analyzer(R) to the U.S. market at RNAi World Congress, which will take place April 30-May 2 in Boston.
RNA-researchers, one of the main user groups of febit’s new device, will benefit from the microarray technology device’s high degree of automation and flexibility. In addition, microRNA researchers will enjoy febit’s recently released microarray based on Sanger miRBase-Version 11.0.
The latest product in febit’s Geniom family, the Geniom RT Analyzer enables the fully automated processing of microarrays on febit’s own Geniom biochips. The compact all-in-one device, which employs microfluidics, provides users with high sample throughput, excellent reproducibility, high sensitivity and a variety of applications. In addition, the product’s freely programmable and precise temperature control optimizes hybridizations and enables the use of enzymatic reactions directly on the microfluidic array for signal enhancement and primer extension assays.
“We have brought together in one benchtop tool the automation of multiple processes involved with the identification and understanding of how genes work,” said Cord Staehler, president and CEO of febit. “This is all about flexibility, control of experiments and time savings. Still, we provide more than a machine with the Geniom RT Analyzer. Our approach is an important combination of tools and talent to help researchers meet their needs. With the demand we’re seeing for the Geniom RT Analyzer, we’re expanding our U.S. sales and support team as well as moving our lab and training center to a larger facility in the Boston area.”
Based on the proven Geniom technology, febit offers microarray analytics for a broad spectrum of DNA and RNA samples. The array design can be chosen from current databases or freely configured by the user. Geniom arrays are produced on demand at febit and subject to rigorous quality control before shipment to the customer.
Alternatively, researchers may prefer the Geniom One(R) System, which enables integrated microarray synthesis in the user’s own laboratory. This provides an independent workflow with complete control of the microarray experiments. For utmost flexibility and maximized throughput, both instruments can be utilized in combination.
About febit
febit is the only company to provide technologies, products and services to effectively read, write and understand the code of life, thus facilitating a systematic understanding for customers in research, diagnostics and biosecurity markets. Geniom applies precision microfluidics to simplify and automate critical steps in making and using microarrays of high quality, providing superior time and cost efficiency. febit’s applications span from genome analysis and diagnostics development to synthetic gene production and industrial biotechnology. febit currently serves the life science research market with instruments, software, consumables and services in the USA and Europe.
CONTACT: Eva Sterzel, Public Relations Manager of febit holding gmbh, +49
(6221) 6510-300, eva.sterzel@febit.de; or David Schull,
david.schull@russopartnersllc.com, or Wendy Lau,
wendy.lau@russopartnersllc.com, both of Russo Partners, LLC for febit
holding gmbh, +1-212-845-4271
Web site: http://www.febit.com/
